C A Higginbotham

Title: C A Higginbotham: Innovator in Radiopharmaceuticals

Introduction

C A Higginbotham is a notable inventor based in Columbia, MO (US). He has made significant contributions to the field of radiopharmaceuticals, particularly in the development of compounds that target specific receptors in cancer treatment.

Latest Patents

Higginbotham holds a patent for "Gastrin receptor-avid peptide conjugates." This innovative compound is designed for use as a therapeutic or diagnostic radiopharmaceutical. It includes a group capable of complexing a medically useful metal, which is attached to a moiety that binds to a gastrin-releasing peptide receptor. The patent outlines a method for treating subjects with neoplastic diseases by administering an effective amount of a radiopharmaceutical that has a metal chelated with a chelating group. This group is linked to a moiety that binds to the gastrin-releasing peptide receptor expressed on tumor cells, facilitating internalization within the cell.

Career Highlights

C A Higginbotham is affiliated with the University of Missouri, where he continues to advance research in the field of radiopharmaceuticals. His work has the potential to significantly impact cancer treatment methodologies.

Collaborations

Higginbotham has collaborated with notable colleagues, including Timothy J Hoffman and Wynn A Volkert. Their combined expertise contributes to the innovative research being conducted at the University of Missouri.

Conclusion

C A Higginbotham's contributions to the field of radiopharmaceuticals exemplify the importance of targeted therapies in modern medicine. His innovative work continues to pave the way for advancements in cancer treatment.